Syndicated P&T Session: Non-Small Cell Lung Cancer
In August 2020 MMIT conducted a syndicated IDN P&T session on Non Small Cell Lung Cancer, focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. The two targeted drugs were indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.
Learn how you can use P&T Perspectives to:
- Gain an understanding of the impact of these agents in NSCLC treatment, and how that might impact your brand.
- Boost your brand by identifying the key differentiators and any unforeseen access barriers
- Gain insights for creating your optimum pricing strategy
- And more
Interested in obtaining the full video and learning more about how you can take advantage of P&T Perspectives?